Variant:
rs28399444 at chr19:41354190 in CYP2A6 (VIP)

Alleles (on + chromosomal strand)
T > TT
T > -
Amino Acid Translation
Lys196Lys
Alternate Name:
CYP2A6:50364-50365delTT

VIP Variant in CYP2A6

This variant (50364-50365delTT) encodes a truncated protein as a result of 2 deleted nucleotides in exon 4, leading to a frameshift that creates a new stop codon in exon 5 [Articles:15993850, 19279561]. rs28399444 is present within the CYP2A6*20 allele, which is associated with decreased CYP2A6 function.

The allele frequency is reported as: 0% in Caucasians, Japanese and Koreans and approximately 1.5% in African Americans [Articles:15993850, 19279561].

Key Publications:
Drugs / Other Molecules
Drug (2)
Diseases Tobacco Use Disorder
Phenotype

When CYP2A6-50364-50365delTT is expressed in E.coli, no coumarin 7-hydroxylation or nicotine C-oxidation activity was detected [Article:15993850]. Individuals possessing CYP2A6*20 alleles demonstrated lower cotinine/nicotine ratios 2 hours after chewing nicotine gum compared to those with CYP2A6*1/*1 genotypes [Article:15993850].

Appendix

Key Haplotypes: CYP2A6*20
Genomic Variant & GenBank ID: T50364del, T50365del on NG_000008.6
mRNA Variant & GenBank ID : 596-597delAA on NM_000762
Protein Variant & GenBank ID: Frameshift resulting in early stop codon at residue 220 in exon 5
gp position: chr19:46046030(hg18)

Connected Drugs

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
coumarin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
nicotine

Connected Diseases

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Tobacco Use Disorder

Publications related to rs28399444 at chr19:41354190: 10

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer research. 2009. Canova Cristina, et al. [Article:19339270@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical pharmacology and therapeutics. 2009. Ho M K, et al. [Article:19279561@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis. 2007. Gemignani Federica, et al. [Article:17259654@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochemical pharmacology. 2005. Fukami Tatsuki, et al. [Article:15993850@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenetics and genomics. 2005. Haberl Michael, et al. [Article:16041240@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004. Solus Joseph F, et al. [Article:15469410@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clinical pharmacology and therapeutics. 2003. Yoshida Ryoko, et al. [Article:12844137@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics. 2003. Kiyotani Kazuma, et al. [Article:14583682@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochemical and biophysical research communications. 2001. Pitarque M, et al. [Article:11394901@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Spontaneous and mutagen-mediated amplification of a neo gene integrated at different genomic sites in rat 2 fibroblasts. Carcinogenesis. 1992. Quinto I, et al. [Article:1547535@PubMed]

Cross-References

UCSC Golden Path:
chr19:41354190
dbSNP:
rs28399444

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.